Executive at Precision BioSciences (DTIL) receives 57,389 RSU compensation award

Rhea-AI Filing Summary

PRECISION BIOSCIENCES INC Chief Research Officer J. Jefferson Smith received a grant of 57,389 Restricted Stock Units. Each unit represents a contingent right to receive one share of common stock, so this award could convert into 57,389 shares if fully vested.

The RSU award vests in three substantially equal annual installments beginning on February 19, 2027, conditioned on Smith’s continued service with the company through each vesting date. Following this grant, Smith’s reported derivative holdings from this award total 57,389 RSUs, reflecting a compensation-related equity grant rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SMITH J. JEFFERSON

Role Chief Research Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	57,389	$0.00	--

Holdings After Transaction: Restricted Stock Units — 57,389 shares (Direct, null)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. Award vests in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Key Figures

RSUs granted: 57,389 units Underlying common stock: 57,389 shares Exercise/convert price: $0.0000 per unit +2 more

5 metrics

RSUs granted 57,389 units Grant to Chief Research Officer on June 1, 2026

Underlying common stock 57,389 shares Each RSU represents one share if vested

Exercise/convert price $0.0000 per unit RSUs granted at no cash exercise price

Vesting schedule start February 19, 2027 Three substantially equal annual installments

Holdings after transaction 57,389 RSUs Total derivative holdings from this award following grant

Key Terms

Restricted Stock Units, contingent right, vesting, derivative

4 terms

Restricted Stock Units financial

"The security title is listed as "Restricted Stock Units" for this grant."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each restricted stock unit represents a contingent right to receive one share."

vesting financial

"Award vests in three substantially equal annual installments beginning on February 19, 2027."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

derivative financial

"The transaction_type is noted as "derivative" for these RSUs."

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SMITH J. JEFFERSON

(Last) (First) (Middle)

C/O PRECISION BIOSCIENCES, INC.

302 E. PETTIGREW STREET, SUITE A-100

(Street)

DURHAM NORTH CAROLINA 27701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PRECISION BIOSCIENCES INC [ DTIL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Research Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/01/2026		A		57,389		(2)	(2)	Common Stock	57,389	$0	57,389	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

2. Award vests in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Remarks:

	/s/ John Alexander Kelly, Attorney-in-Fact for J. Jefferson Smith	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PRECISION BIOSCIENCES (DTIL) report for J. Jefferson Smith?

PRECISION BIOSCIENCES reported that Chief Research Officer J. Jefferson Smith received a grant of 57,389 Restricted Stock Units. These RSUs represent a compensation award that may convert into common shares over time if vesting conditions tied to continued service are satisfied.

How many Restricted Stock Units did DTIL grant to its Chief Research Officer?

DTIL granted 57,389 Restricted Stock Units to Chief Research Officer J. Jefferson Smith. Each RSU corresponds to a contingent right to receive one share of common stock, creating potential future equity ownership if the award fully vests under its service conditions.

What are the vesting terms for J. Jefferson Smith’s DTIL RSU award?

The RSU award vests in three substantially equal annual installments beginning on February 19, 2027. Vesting is subject to Smith’s continued service with Precision BioSciences through each applicable vesting date, so the award delivers value gradually over a multi-year period.

Does the DTIL Form 4 show an open-market stock purchase or sale by J. Jefferson Smith?

The Form 4 does not show an open-market purchase or sale; it reports a grant of 57,389 Restricted Stock Units as compensation. The transaction code is A, indicating a grant or award acquisition rather than a discretionary market trade in DTIL common stock.

How many DTIL RSUs does J. Jefferson Smith hold after this reported transaction?

After this reported transaction, J. Jefferson Smith’s holdings from this RSU award total 57,389 Restricted Stock Units. These RSUs are derivative securities that may settle into the same number of common shares if the multi-year vesting and continued service conditions are met.